G M Davies1, D J Watson, N Bellamy. 1. Department of Epidemiology, Merck Research Laboratories, West Point, PA 19486-0004, USA.
Abstract
OBJECTIVE: This study compares the responsiveness and relative effect sizes of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) with the Medical Outcomes Study Short Form Health Survey (SF-36) in a randomized clinical trial for treatment of osteoarthritis (OA). METHODS:Patients with OA of the knee or hip were randomized to receive either placebo or 2,400 mg/day of ibuprofen for 28 days. Patients completed the WOMAC and SF-36 at baseline and days 7, 14, and 28 of the trial. RESULTS: Patients receiving ibuprofen showed significant improvement in WOMAC pain, physical functioning, and the total score, while improvement was detected only for bodily pain on the SF-36. The WOMAC detected significant differences between ibuprofen and placebo for pain and physical functioning, whereas the SF-36 detected differences for the bodily pain subscale. CONCLUSION: These results suggest the WOMAC has greater power to detect treatment differences than the SF-36, with respect to pain and physical functioning, in OA clinical trials.
RCT Entities:
OBJECTIVE: This study compares the responsiveness and relative effect sizes of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) with the Medical Outcomes Study Short Form Health Survey (SF-36) in a randomized clinical trial for treatment of osteoarthritis (OA). METHODS:Patients with OA of the knee or hip were randomized to receive either placebo or 2,400 mg/day of ibuprofen for 28 days. Patients completed the WOMAC and SF-36 at baseline and days 7, 14, and 28 of the trial. RESULTS:Patients receiving ibuprofen showed significant improvement in WOMAC pain, physical functioning, and the total score, while improvement was detected only for bodily pain on the SF-36. The WOMAC detected significant differences between ibuprofen and placebo for pain and physical functioning, whereas the SF-36 detected differences for the bodily pain subscale. CONCLUSION: These results suggest the WOMAC has greater power to detect treatment differences than the SF-36, with respect to pain and physical functioning, in OA clinical trials.
Authors: Brian M Ilfeld; R Scott Meyer; Linda T Le; Edward R Mariano; Brian A Williams; Krista Vandenborne; Pamela W Duncan; Daniel I Sessler; F Kayser Enneking; Jonathan J Shuster; Rosalita C Maldonado; Peter F Gearen Journal: Anesth Analg Date: 2009-04 Impact factor: 5.108
Authors: Brian M Ilfeld; Scott T Ball; Peter F Gearen; Edward R Mariano; Linda T Le; Krista Vandenborne; Pamela W Duncan; Daniel I Sessler; F Kayser Enneking; Jonathan J Shuster; Rosalita C Maldonado; R Scott Meyer Journal: Anesth Analg Date: 2009-08 Impact factor: 5.108
Authors: Matthias Rother; Bernard J Lavins; Werner Kneer; Klaus Lehnhardt; Egbert J Seidel; Stefan Mazgareanu Journal: Ann Rheum Dis Date: 2007-03-15 Impact factor: 19.103
Authors: Garry R Barton; Tracey H Sach; Anthony J Avery; Michael Doherty; Claire Jenkinson; Kenneth R Muir Journal: Cost Eff Resour Alloc Date: 2009-07-17